retatrutide approval status 2025 retatrutide fda approval is everywhere right now and I get asked about it almost daily. Looking at the evidence: Early phase 3 data released by Eli Lilly showed ~28–29% average weight loss at the Retatrutide approval: FDA status, clinical

The commercial game for positions 2 through 5 in the triple-agonist category is not "match Retatrutide's 28.7%." It is "deliver 20-24% at a materially lower price, with a better tolerability profile, or via an oral formulation that improves compliance." 5.4 The Dysesthesia Signal and What It Implies Mechanistically Retatrutide's TRIUMPH-4 readout reported dysesthesia - abnormal sensory nerve sensations including tingling, burning, or reduced sensation - at 8% on the 9 mg arm and 20.9% on the 12 mg arm

The Journal of Immunology

2026 Rate Changes - Massachusetts: +11.7% avg

Conti, V

Specifically, here is the timeline so far: Phase 1: Completed

Intracellular GSH levels can be a very useful indicator for overall cell health, proliferation, and death (2)